Last Updated : November 21, 2023
Details
Generic Name:
secukinumab
Project Status:
Suspended
Therapeutic Area:
Hidradenitis suppurativa
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cosentyx
Project Line:
Reimbursement Review
Project Number:
SR0781-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Cosentyx is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Cosentyx is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 28-Mar-23 |
|---|---|
| Call for patient/clinician input closed | 23-May-23 |
| Clarification: - Patient input submission received from the Canadian Skin Patient Alliance (CSPA), HS Heroes, and Hidradenitis & Me Support Group | |
| Submission received | 10-May-23 |
| Submission accepted | 25-May-23 |
| Clarification: - CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements. - Submission temporarily suspended | |
| Review initiated | 26-May-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 10-Aug-23 |
| Deadline for sponsors comments | 21-Aug-23 |
| CADTH review report(s) and responses to comments provided to sponsor | 15-Sep-23 |
| Expert committee meeting (initial) | 27-Sep-23 |
Last Updated : November 21, 2023